Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aroa Biosurgery Ltd ( (AU:ARX) ) has shared an announcement.
Aroa Biosurgery Limited announced the cessation of John Pinion as a director, effective October 31, 2025. This update includes details of his interests in the company’s securities, which consist of fully paid ordinary shares and options. The announcement is part of the company’s compliance with ASX listing rules and may have implications for its governance and strategic direction.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery Limited operates in the biosurgery industry, focusing on developing and manufacturing regenerative tissue products. The company provides solutions for soft tissue repair and complex wounds, aiming to enhance healing and improve patient outcomes.
Average Trading Volume: 270,603
Technical Sentiment Signal: Buy
Current Market Cap: A$267.4M
Find detailed analytics on ARX stock on TipRanks’ Stock Analysis page.